|
|
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | SalioGen's Sujit Jain shares his assessment of the partnering landscape for mRNA therapeutic candidates. Though capacity has been a hot-button topic/need for other modalities in the ATMP space, his tips for evaluating CDMOs for mRNA therapeutics keep us aligned around the importance of capability and flexibility in outsourcing partnerships. |
|
|
|
|
| Scalable mRNA Affinity Capture | Application Note | By Jenny England, Ph.D., Thermo Fisher Scientific Bioproduction | The POROS Oligo dT(25) affinity resin offers a solution for the purification of mRNA by providing efficient purification, high binding capacity, and selectivity while removing impurities. |
|
|
| Treating Deficiencies In Employee Training And Mentorship | Article | By Jenny Minigh, inSeption Group | Investing in employee training and development is not just beneficial for the employees. It also contributes significantly to the organization’s success and provides a competitive advantage. |
|
|
|
| Ophthalmic Drug Delivery | Article | By Dr. Tamas Solymosi, Nanoform | Explore the challenges to effective delivery of drugs to the eye, intricacies of ophthalmic drug delivery, and advantages of nanoparticles as an enabling technology for ocular drug delivery systems. |
|
|
|
FEATURED EDITORIALS CONTINUED... |
|
|
|
By Brian Glass, Pharmatech Associates — a USP company | Plasmid DNA (pDNA) is used in gene therapies, vaccines, and RNA therapeutics. Along each step of development, we need to evaluate potential impurities. |
|
|
|
Arcturus’ Ye Zhang shares the behind-the-scenes best practices the company implemented that led to the approval of the world’s first saRNA vaccine in Japan. |
|
|
.png){kind=logo}
